Stocks of SeqLL Inc. (NASDAQ:SQL) traded higher last session on Wall Street, down -3.74% to $0.54.
According to the data, SeqLL Inc. (NASDAQ:SQL) has 1 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $1.50 and a low of $1.50, we find $1.50. Given the previous closing price of $0.56, this indicates a potential upside of 167.86 percent. SQL stock price is now 31.42% away from the 50-day moving average and -7.46% away from the 200-day moving average. The market capitalization of the company currently stands at $8.70M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
A total of 0 analysts have issued a hold rating and 1 have given it a buy rating. Brokers who have rated the stock have averaged $1.50 as their price target over the next twelve months.
.
In other news, Miscoll Douglas Patrick, Director bought 1,500 shares of the company’s stock on Dec 19. The stock was bought for $495 at an average price of $0.33. Upon completion of the transaction, the Director now directly owns 103,736 shares in the company, valued at $56017.44. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 16, Director Miscoll Douglas Patrick bought 1,500 shares of the business’s stock. A total of $525 was incurred on buying the stock at an average price of $0.35. This leaves the insider owning 103,736 shares of the company worth $56017.44. A total of 22.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SQL stock. A new stake in SeqLL Inc. shares was purchased by AWM INVESTMENT COMPANY, INC. during the first quarter worth $274,000. RENAISSANCE TECHNOLOGIES LLC invested $99,000 in shares of SQL during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in SeqLL Inc. valued at approximately $42,000. GEODE CAPITAL MANAGEMENT, LLC acquired a new stake in SQL for approximately $32,000. SHAY CAPITAL LLC purchased a new stake in SQL valued at around $28,000 in the second quarter. In total, there are 6 active investors with 0.20% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $0.4400 for SeqLL Inc. (NASDAQ: SQL). During the past 12 months, SeqLL Inc. has had a low of $0.23 and a high of $2.40. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.60, and a quick ratio of 4.60. The fifty day moving average price for SQL is $0.4135 and a two-hundred day moving average price translates $0.5788 for the stock.
The latest earnings results from SeqLL Inc. (NASDAQ: SQL) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.1, missing analysts’ expectations of -$0.08 by -0.02. This compares to -$0.08 EPS in the same period last year.
SeqLL Inc.(SQL) Company Profile
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company’s True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice’s Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
